## **ASTRAZENECA PLC ADR**

ISIN: **US0463531089** WKN: 046353108 Asset Class: Stock

77.50 Company 2024/04/10 21:38:25 75.00 **Price** 72.50 67.95 AstraZeneca USD 70.00 **Difference** 67.50 -0.68%(-0.47) 65.00 **Contact Details** 62.50 ASTRAZENECA PLC


Tel: +44-20-3749-5000

Fax: +

Cambridge Biomedical Campus, Web:

1 Francis Crick Avenue http://www.astrazeneca.co.uk

CB2 0AA Cambridge E-mail: -



### **Company Profile**

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

## Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	19,653,278,000		18,782,109,000		19,376,130,000	
Common stock capital		304,361,000		321,722,000		285,724,000
Fixed assets	59,668,183,000		61,426,552,000		58,414,116,000	
Equity capital of a company		30,723,250,000		30,807,215,000		29,005,869,000
Cash and cash equivalents	4,581,110,000		5,125,945,000		4,672,745,000	
Accrued liabilities		2,076,404,000		1,715,853,000		2,517,627,000
Other assets	-		-		-	
Current liabilities		23,958,267,000		21,858,009,000		16,681,309,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		24,639,943,000		27,543,436,000		32,103,067,000
Different income		-		-		-
Other liabilities		2,116,410,000		3,686,091,000		3,675,292,000
Total assets	79,321,462,000	79,321,462,000	80,208,662,000	80,208,662,000	77,790,246,000	77,790,246,000

#### **Balance notes**

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	89,900	83,500	83,100
Equity ratio	38.76%	38.43%	37.31%
Debt-equity ratio	158.03%	160.21%	168.06%

#### **Others**

	2023	2022	2021
Tax Expense Rate	13.57%	-31.60%	189.05%

# **ASTRAZENECA PLC ADR**

ISIN: US0463531089 WKN: 046353108 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	36,853,651,000	36,005,612,000	27,508,829,000
Net income	4,790,628,000	2,669,307,000	81,436,000
EBIT	7,269,613,458	3,139,055,947	475,500,519
Operating income before taxes	5,559,703,000	2,034,453,000	-146,149,000
Cash Flow	8,553,142,000	8,011,169,000	4,360,490,000
Net interest income	-676,560,000	-658,396,000	-554,059,000
Research and development expenses	8,322,259,000	7,825,259,000	6,214,626,000
Income taxes	754,594,000	-642,971,000	-276,302,000
Result from investments in subsidaries, associates and other	-9,653,000	-4,059,000	-46,535,000
Revenues per employee	477,868	502,656	385,885

<b>Board of Directors</b>	
Michel Demaré	Chairman of Supervisory Board
Andreas Rummelt	Member of Supervisory Board
Aradhana Sarin	Member of Supervisory Board
Euan Ashley	Member of Supervisory Board
Nazneen Rahman	Member of Supervisory Board
Tony Mok	Member of Supervisory Board
Anna Olive Magdelene Manz	Member of Supervisory Board
Deborah DiSanzo	Member of Supervisory Board
Diana Layfield	Member of Supervisory Board
Marcus Wallenberg	Member of Supervisory Board
Philip Broadley	Member of Supervisory Board
Sherilyn McCoy	Member of Supervisory Board

Members of Management Board			
Pascal Soriot	Chairman of Managing Board		
Aradhana Sarin	Member of Executive Committee		
David Fredrickson	Member of Executive Committee		
Iskra Reic	Member of Executive Committee		
Jeff Pott	Member of Executive Committee		
Leon Wang	Member of Executive Committee		
Marc Dunoyer	Member of Executive Committee		
Menelas Pangalos	Member of Executive Committee		
Pam Cheng	Member of Executive Committee		
President AstraZeneca AB, Sweden	Member of Executive Committee		
Ruud Dobber	Member of Executive Committee		
Susan Galbraith	Member of Executive Committee		